8-K: Insmed Reports Strong Q3 Revenue Growth, BRINSUPRI FDA Approval

Insmed announced robust third-quarter 2025 financial results, driven by significant ARIKAYCE growth and the successful U.S. launch of its newly FDA-approved BRINSUPRI for non-cystic fibrosis bronchiectasis.

Summary

• Total revenues for the third quarter of 2025 reached $142.3 million, a 52% increase compared to $93.4 million in the third quarter of 2024.
• ARIKAYCE generated $114.3 million in total revenue for Q3 2025, reflecting 22% growth over Q3 2024, with U.S. revenue at $74.0 million (11% growth) and international revenue at $40.3 million (52% growth).
• BRINSUPRI (brensocatib) received FDA approval in August 2025 as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) and was commercially launched in the U.S., generating $28.1 million in its first partial quarter.
• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending BRINSUPRI's approval in the EU in October 2025, with regulatory submissions also accepted in the UK and Japan.
• Insmed raised its full-year 2025 global ARIKAYCE revenue guidance to a range of $420 million to $430 million, up from $405 million to $425 million previously, representing 15% to 18% year-over-year growth.
• Net loss for Q3 2025 was $370.0 million, or $1.75 per share, compared to a net loss of $220.5 million, or $1.27 per share, for Q3 2024, primarily due to increased R&D and SG&A expenses.
• The company ended Q3 2025 with approximately $1.7 billion in cash, cash equivalents, and marketable securities.
• Key pipeline updates include anticipated topline data for the Phase 2b BiRCh study (CRSsNP) by early January 2026 and the Phase 2b CEDAR study (HS) in the first half of 2026, with CEDAR enrollment completed ahead of schedule.
• The PALM-ILD Phase 3 study of TPIP (PH-ILD) is expected to initiate in Q4 2025, with additional Phase 3 studies for PAH, PPF, and IPF planned for 2026.
• In gene therapy, the Phase 1 ASCEND study (INS1201 for DMD) completed dosing of its first cohort, and the IND for INS1202 (ALS) has been cleared by the FDA.

Sentiment

Score: 8

Explanation: The company demonstrated strong commercial execution with a new product launch and raised guidance for an existing product, coupled with significant pipeline advancements across multiple therapeutic areas. While net loss increased due to strategic investments in R&D and SG&A for future growth, the overall operational momentum and strong cash position indicate a very positive outlook.

Positives

• BRINSUPRI received FDA approval in August 2025 as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) and was successfully launched in the U.S.
• BRINSUPRI generated $28.1 million in revenue in its first partial quarter of U.S. commercialization.
• The CHMP adopted a positive opinion recommending BRINSUPRI's approval in the EU, indicating strong potential for international expansion.
• ARIKAYCE global revenue grew 22% to $114.3 million in Q3 2025 compared to Q3 2024, with international revenue growing 52%.
• The company raised its full-year 2025 global ARIKAYCE revenue guidance to $420 million to $430 million, reflecting 15% to 18% year-over-year growth.
• Enrollment for the Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) was completed ahead of schedule.
• The Phase 1 ASCEND clinical study of INS1201, a gene therapy for Duchenne muscular dystrophy (DMD), completed dosing of its first cohort with no concerning safety signals observed.
• The Investigational New Drug (IND) filing for INS1202, a gene therapy for Amyotrophic lateral sclerosis (ALS), has been cleared by the FDA.
• Insmed maintains a strong capital position with approximately $1.7 billion in cash, cash equivalents, and marketable securities as of September 30, 2025.
• The company earned the No. 1 ranking in Science's 2025 Top Employers Survey for the fifth consecutive year, indicating strong organizational health and talent attraction.

Negatives

• Net loss for the third quarter of 2025 increased to $370.0 million, or $1.75 per share, compared to $220.5 million, or $1.27 per share, for the third quarter of 2024.
• Research and development (R&D) expenses increased to $186.4 million in Q3 2025 from $150.8 million in Q3 2024, reflecting significant investment but contributing to the net loss.
• Selling, general and administrative (SG&A) expenses increased to $186.4 million in Q3 2025 from $118.9 million in Q3 2024, driven by BRINSUPRI commercialization efforts and headcount increases.
• Approximately 40% of BRINSUPRI's Q3 sales were attributed to inventory stocking, which is not anticipated to be as impactful in Q4, suggesting a potential slowdown in reported sales growth for the next quarter.
• The change in fair value of deferred and contingent consideration liabilities significantly increased to $104.7 million in Q3 2025 from $14.7 million in Q3 2024, impacting operating loss.

Risks

• Failure to continue to successfully commercialize ARIKAYCE in the U.S., Europe, or Japan, or BRINSUPRI in the U.S., or to maintain regulatory approvals.
• Inability to obtain full approval of ARIKAYCE from the FDA, including failure to complete the confirmatory post-marketing clinical trial required for full approval, or failure to obtain regulatory approval to expand ARIKAYCE's indication.
• Failure to obtain, or delays in obtaining, regulatory approvals for product candidates in the U.S., Europe, or Japan, or for ARIKAYCE outside these regions, including separate regulatory approval for the Lamira Nebulizer System.
• Uncertainties or changes in the degree of market acceptance of marketed products or product candidates by physicians, patients, and third-party payors.
• Inability to obtain and maintain adequate reimbursement from government or third-party payors for marketed products or product candidates, or acceptable prices.
• Inaccuracies in estimates of potential market sizes, patient uptake rates, treatment duration, or adherence/discontinuation rates.
• Failure of third parties to manufacture sufficient quantities of products for commercial or clinical needs, conduct clinical trials, or comply with agreements and regulations.
• Risks associated with the senior secured loan and royalty financing, including maintaining compliance with covenants and the impact of operational restrictions.
• Inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties for distribution.
• Failure to successfully conduct future clinical trials for marketed products or product candidates, or inability to enroll or retain sufficient patients.
• Development of unexpected safety or efficacy concerns related to marketed products or product candidates.
• Risks that clinical studies will be delayed, serious side effects will be identified, or protocol amendments will be rejected.
• Failure to successfully predict the time and cost of development, regulatory approval, and commercialization for novel gene therapy products.
• Risk that interim, topline, or preliminary data from clinical trials may change as more patient data become available or be interpreted differently.
• Risk that competitors may obtain orphan drug exclusivity for a similar product.
• Inability to attract and retain key personnel or to effectively manage growth.
• Inability to successfully integrate acquisitions and manage management's time devoted to integration activities.
• Risks that acquired technologies, products, and product candidates will not be commercially successful.
• Inability to adapt to a highly competitive and changing environment.
• Inability to access, upgrade, or expand technology systems or difficulties in updating existing technology or developing new technology.
• Risk that the company is unable to maintain significant customers.
• Risk that government healthcare reform materially increases costs and damages financial condition.
• Business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises.
• Risk that current and potential future use of AI and machine learning may not be successful.
• Deterioration in general economic conditions globally, including the effect of prolonged periods of inflation.
• Risk of involvement in costly intellectual property disputes, inability to protect intellectual property rights, or prevent disclosure of trade secrets.
• Restrictions or other obligations imposed by agreements related to marketed products or product candidates, including license agreements.
• The cost and potential reputational damage resulting from litigation, including product liability claims.
• Risk that operations are subject to a material disruption in the event of a cybersecurity attack or issue.
• Limited experience operating internationally.
• Changes in laws and regulations applicable to the business, including pricing reform and laws impacting the ability to utilize certain third parties.
• History of operating losses and the possibility of never achieving or maintaining profitability.
• Goodwill impairment charges affecting results of operations and financial condition.
• Inability to repay existing indebtedness and uncertainties with respect to the ability to access future capital.
• Delays in the execution of plans to build out an additional third-party manufacturing facility and unexpected expenses associated with those plans.

Future Outlook

Insmed anticipates a period of significant commercial and clinical catalysts over the next 18 months. For ARIKAYCE, topline data from the Phase 3 ENCORE trial is expected in the first half of 2026, potentially leading to a supplementary new drug application (sNDA) for all MAC lung disease patients in the U.S. in the second half of 2026. BRINSUPRI is projected for commercial launches in the EU, UK, and Japan in 2026, following anticipated regulatory approvals. The brensocatib pipeline includes topline data from the Phase 2b BiRCh study by early January 2026 and the Phase 2b CEDAR study in the first half of 2026. TPIP's development is accelerating with the initiation of the PALM-ILD Phase 3 study in Q4 2025, followed by Phase 3 studies for PAH in early 2026, and for PPF and IPF in the second half of 2026. The gene therapy pipeline is also advancing, with an IND filing for a Stargardt disease candidate expected in the first half of 2026, and the company aims to submit an average of one to two INDs per year from its pre-clinical programs.

Management Comments

• "The third quarter of 2025 celebrated the FDA approval of BRINSUPRI and the availability of our second commercial product, underscoring our teams dedication to bringing forward a first-in-disease therapy for patients with non-cystic fibrosis bronchiectasis. While still early in the U.S. BRINSUPRI launch, we are very encouraged by positive feedback received from both physicians and patients."
• "This achievement is just the beginning of numerous commercial and clinical catalysts anticipated over the next 18 months across our late-stage programs – ARIKAYCE, brensocatib, and TPIP – and our growing clinical pipeline of firstor best-in-class therapies."
• "With these opportunities ahead, our team is more dedicated than ever to transforming the lives of patients with serious diseases."

Industry Context

The approval of BRINSUPRI as the first-in-disease therapy for non-cystic fibrosis bronchiectasis (NCFB) positions Insmed as a significant innovator in the rare respiratory disease market, addressing a substantial unmet medical need. This achievement, coupled with the continued strong performance and raised guidance for ARIKAYCE, reinforces Insmed's leadership in specialized biopharmaceutical segments. The company's robust pipeline, spanning pulmonary, inflammatory, and gene therapy areas, demonstrates a strategic focus on developing firstor best-in-class therapies, aligning with broader industry trends towards precision medicine and addressing rare diseases. The consistent recognition as a top employer in science also highlights its ability to attract and retain top talent, a critical factor for success in the highly competitive biopharmaceutical R&D landscape.

Comparison to Industry Standards

• Insmed's ambition for BRINSUPRI sales is to perform in-line with historically strong respiratory launches, indicating a high benchmark for its new product's commercial success.
• For the Phase 2b BiRCh study of brensocatib in CRSsNP, a 'Clear Win' is defined as an sTSS improvement matching historically approved levels, specifically referencing a 0.7-point improvement achieved by XHANCE in its Phase 3 ReOpen2 trial, which received FDA approval in March 2024.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, raised guidance, successful new product launch, and a robust pipeline with multiple near-term catalysts.
• Patients: Access to a new FDA-approved first-in-disease therapy (BRINSUPRI) for NCFB and continued development of therapies for other serious diseases, including MAC lung disease, PH-ILD, PAH, PPF, IPF, DMD, and ALS.
• Employees: Recognition as a top employer for the fifth consecutive year, indicating a positive work environment and strong talent retention, with increased headcount supporting growth initiatives.
• Customers (Physicians/Healthcare Providers): New treatment options for patients with NCFB and continued availability and potential label expansion for ARIKAYCE, supported by ongoing clinical research.
• Suppliers/Partners: Continued demand for manufacturing and clinical trial services due to expanding product portfolio and pipeline activities.

Next Steps

• Anticipate EMA decision for BRINSUPRI by year-end 2025.
• Initiate PALM-ILD, a Phase 3 study of TPIP in patients with PH-ILD, in the fourth quarter of 2025.
• Report topline data from the Phase 2b BiRCh study of brensocatib in patients with CRSsNP by early January 2026.
• Initiate a Phase 3 study of TPIP in patients with pulmonary arterial hypertension (PAH) in early 2026.
• Launch BRINSUPRI commercially in the EU by early 2026, pending approval.
• Report topline data from the Phase 2b CEDAR study of brensocatib in patients with HS in the first half of 2026.
• Report topline readout of the Phase 3 ENCORE trial for ARIKAYCE in the first half of 2026.
• File an IND for Insmed's third gene therapy candidate targeting Stargardt disease in the first half of 2026.
• Receive decision on UK regulatory submission for brensocatib in the first half of 2026.
• Submit a supplementary new drug application (sNDA) to the U.S. FDA for ARIKAYCE in all patients with MAC lung disease in the second half of 2026, assuming successful ENCORE trial results.
• Launch BRINSUPRI commercially in the UK and Japan in 2026, pending approval.
• Initiate additional Phase 3 studies of TPIP in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) in the second half of 2026.
• Expect first next-gen DPP1 candidate (INS1033) to enter clinic in 2026.
• Submit an average of one to two INDs per year from pre-clinical research programs.

Key Dates

Recommendation

The company demonstrated strong commercial execution with the successful U.S. launch of BRINSUPRI, a first-in-disease therapy, and robust 22% year-over-year growth for ARIKAYCE, leading to raised full-year revenue guidance. The pipeline is advancing rapidly with multiple late-stage clinical readouts and new Phase 3 initiations anticipated within the next 18 months, including significant gene therapy progress. While net loss increased due to strategic investments in R&D and commercialization, these are expected to drive substantial future growth and market expansion. The strong cash position of $1.7 billion provides ample runway for these initiatives, making it an attractive investment for long-term growth.

Keywords

Biopharmaceutical, Non-Cystic Fibrosis Bronchiectasis, NCFB, Mycobacterium avium complex lung disease, MAC lung disease, ARIKAYCE, BRINSUPRI, Brensocatib, TPIP, Gene Therapy, Pulmonary Hypertension, FDA Approval, Clinical Trials, Financial Results, Rare Diseases, Orphan Drugs, Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Hidradenitis Suppurativa, Chronic Rhinosinusitis without Nasal Polyps